Introduction Philipps-University is a traditional German institution and the oldest Protestant university in the world, founded in 1527. It has been a center for research and education for almost five centuries. |
Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Immune System Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Polyclonal antibody | 1 |
ASO | 1 |
Target |
Mechanism GATA3 inhibitors |
Originator Org. |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MERS-CoV spike protein inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism APP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date13 May 2024 |
Sponsor / Collaborator |
Start Date27 Apr 2024 |
Sponsor / Collaborator |
Start Date24 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Antisense oligonucleotide therapeutics(sterna) ( GATA3 ) | Asthma More | Phase 2 |
DG172 ( PPARδ ) | - | Preclinical |
Plasmin Inhibitor (Philipps University Marburg) ( Plasmin ) | - | Preclinical |
MI-1148 ( FURIN ) | influenza A subtype H7N1 infection More | Preclinical |
nAbs-Abeta ( APP ) | Alzheimer Disease More | Preclinical |